RECEIVED
CENTRAL FAX CENTER
AUG 2 9 2006

LISTING OF THE CLAIMS

Please cancel claims 19-27 without prejudice or disclaimer, please amend claims 28, 29 and 44 and please add new claims 48-59. The following listing of the claims will replace all prior versions, and listings, of claims in the application:

1. -27. (Canceled)

28. (Currently Amended) A method for treating a solid cancer or h[e]aematological malignancy ~~in a patient~~ comprising administering to a patient in need thereof a composition comprising: (a) one or more steroids ~~which are not~~excluding cytostaticum, wherein the ~~composition~~ steroid is ~~conjugated~~covalently attached to ~~with~~ a ~~mammalian~~ protein excluding an antibody, ~~the composition further comprising;~~ and (b) a cytoskeleton-acting drug.

29. (Currently Amended) The method of claim 28, wherein the solid cancer is one of prostate adenocarcinoma (hormone sensitive or resistant) and ~~its~~ metastases thereof, breast cancer and ~~its~~ metastases thereof ~~in any places~~, pheochromocytomas and ~~their~~ metastases thereof, bone tumor and ~~their~~ metastases thereof and brain tumor (neuroblastomas).

30. (Previously Presented) The method of claim 28, wherein the haematological malignancies are acute and chronic myeloid leukemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).

31. (Previously Presented) The method of claim 28, wherein the steroid is an androgen.

32. (Previously Presented) The method of claim 31, wherein the androgen is testosterone.

33. (Previously Presented) The method of claim 28, wherein the mammalian protein is a recombinant or isolated natural serum albumin.

34. (Previously Presented) The method of claim 28, wherein the composition is detectably-labeled.

35. (Previously Presented) The method of claim 32, wherein the testosterone is covalently attached to the mammalian protein through a carboxy-methyl ether linker.

36. (Previously Presented) The method of claim 35, wherein the linker is covalently attached to the testosterone at the 3' position of the steroidal ring.

37. (Previously Presented) The method of claim 28, wherein the cytoskeleton-acting drug is Taxol or Taxotere.

38. (Withdrawn) The method of claim 28, the composition further comprises an antiandrogen.

39. (Withdrawn) The method of claim 38, wherein the antiandrogen is present in about a 10-fold molar excess relative to the molar amount of the one more steroids.

40. (Withdrawn) The method of claim 28, wherein the administration of the composition is parenteral, percutaneous or intravenous.

41. (Previously Presented) The method of claim 28, wherein the composition is administered at least once daily.

42. (Withdrawn) The method of claim 28, wherein the method further comprises the step of administering an antiandrogen to the patient.

43. (Previously Presented) The method of claim 28, wherein the method further comprises the step of decreasing solid cancer mass in the patient.

44. (Currently Amended) A method for treating prostate cancer comprising administering to a patient in need thereof ~~in a patient, the method comprising the step of administering~~ a composition comprising ~~a compound with the following formula: [~~Testosterone3-(O-carboxymethyl)oxime-human serum albumin~~], the composition further comprising~~ and Taxol or Taxotere.

45. (Previously Presented) The method of claim 44, wherein the composition further comprises an antiandrogen.

46. (Previously Presented) The method of claim 44, wherein the method further comprises the step of administering an antiandrogen to the patient.

47. (Previously Presented) The method of claim 44, wherein the method further comprises the step of decreasing prostate cancer mass in the patient.

48. (New) A method for treating a solid cancer or haematological malignancy comprising administering to a patient in need thereof a composition comprising: (a) one or more steroids excluding cytostaticum, wherein the steroid is covalently attached to a mammalian protein selected from the group consisting of a globular protein, a plasma protein, albumin and a binder; and (b) a cytoskeleton-acting drug.

49. (New) The method of claim 48, wherein the solid cancer is one of prostate adenocarcinoma (hormone sensitive or resistant) and metastases thereof, breast cancer and metastases thereof, pheochromocytomas and metastases thereof, bone tumor and metastases thereof and brain tumor (neuroblastomas).

50. (New) The method of claim 48, wherein the haematological malignancies are acute and chronic myeloid leukemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).

51. (New) The method of claim 48, wherein the steroid is an androgen.

52. (New) The method of claim 51, wherein the androgen is testosterone.

53. (New) The method of claim 48, wherein the mammalian protein is a recombinant or isolated natural serum albumin.

54. (New) The method of claim 48, wherein the composition is detectably-labeled.

55. (New) The method of claim 52, wherein the testosterone is covalently attached to the mammalian protein through a carboxy-methyl ether linker.

56. (New) The method of claim 55, wherein the linker is covalently attached to the testosterone at the 3' position of the steroidal ring.

57. (New) The method of claim 48, wherein the cytoskeleton-acting drug is Taxol or Taxotere.

58. (New) The method of claim 48, wherein the composition is administered at least once daily.

59. (New) The method of claim 48, wherein the method further comprises the step of decreasing solid cancer mass in the patient.